Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
Status:
Completed
Trial end date:
2018-04-16
Target enrollment:
Participant gender:
Summary
This will be a randomized phase II clinical trial of patients with histologic documentation
of metastatic colorectal cancer, who have received local and currently approved standard
therapies, excluding RGF.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio